p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry
Jazyk angličtina Země Slovensko Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
10732868
Knihovny.cz E-zdroje
- MeSH
- aktivace transkripce MeSH
- dospělí MeSH
- imunohistochemie metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorové buňky kultivované MeSH
- nádorový supresorový protein p53 analýza genetika MeSH
- nádory prsu chemie MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- nádorový supresorový protein p53 MeSH
The prognostic and predictive value of p53 mutation in breast cancer is still conflicting. The choice of the p53 status detection method may account for some discrepancies. In this pilot study we compared two differently-based methods for detection of p53 alteration in 32 breast carcinoma samples: the immunohistochemical method using Bp53, DO1 and DO11 monoclonal antibodies for analysis of the p53 protein accumulation in cell nuclei and the functional method FASAY. FASAY - functional analysis of the separated alleles in yeast - tests the capability of the human p53 to transactivate a reporter with a p53 binding site RGC driving the ADE2 gene in yeast. In our group the percentage of breast cancers with accumulated p53 protein was 50%, as well as percentage of mutant p53 scored by FASAY was 50%. Although the agreement of both methods, when comparing the results of individual patients was high (94%), our results show that immunohistochemistry does not reflect the p53 status quite exactly.
High frequency of temperature-sensitive mutants of p53 in glioblastoma
